Interview: How 4.5MM Late-Stage Neuro Patients Drive Opportunity For MRI Interventions Print E-mail
By Staff and Wire Reports   
Tuesday, 18 September 2012 13:32

icon_ceoexclusive2.2 Million late-stage neuro-patients are "stranded", according to MRI Interventions (OTCBB:MRIC) CEO Kimble Jenkins, who explains that neurosurgeons have been performing minimally invasive brain surgeries using technologies dating back at least 60 years.

"The surgeons essentially perform these procedures blind," says Jenkins, whose company has developed a next-generation imaging platform that allows neurosurgeons to see inside a patient's brain in real-time during procedures. 

The company hopes to revolutionize neurosurgery using MRI imaging similar to how the endoscope revolutionized orthopedic surgery or how fluoroscopy changed the dynamics of cardiovascular procedures. 

Worldwide, the company estimates there are 4.5 Million late-stage neuro patients that could benefit from a platform that enables targeted deep-brain stimulation, focal ablation, and direct drug delivery therapies. Communities' desire to take care of patients with treatment-resistant Parkinson's, Alzheimer's, Brain Tumors, OCD, and other neurologic diseases drives a very large opportunity for MRI Interventions, likening the company to names such as MAKO Surgical (NASDAQ:MAKO) or Intuitive Surgical (NASDAQ:ISRG), which drive value via superior surgical platforms in other areas. 

Companies such as CellDex Therapeutics (NASDAQ:CLDX), ImmunoCellular Therapeutics (AMEX:IMUC) or Agenus (NASDAQ:AGEN), who are developing experimental therapies targeting brain tumors, can utilize MRI Interventions’ technology as a direct delivery platform for their drugs. In facilitating the delivery of these, and other, experimental therapies, MRI Interventions creates risk-mitigated exposure to the future of treating neurologic diseases. As an intermediary in the delivery of therapeutics, MRI Interventions benefits from the recurring use of its technology, which drives revenues and cash-flows. 

In an exclusive video interview, MRI Interventions Chief Executive Officer, Kimble Jenkins, discusses the company's outlook and growth prospects, utilization of ClearPoint - the company's MRI-guided visualization platform - and research & development efforts, particularly a next-generation visualization platform that will guide surgeons in catheter-based cardiac EP procedures.





"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter